Used primarily in neuroscience research, this compound (commonly known as DNQX) acts as a selective antagonist for non-NMDA glutamate receptors, particularly the AMPA and kainate receptor subtypes. It is instrumental in studying the role of glutamate in synaptic transmission, plasticity, and excitotoxicity, often by isolating NMDA receptor-mediated responses. Researchers utilize it to explore neurological disorders such as epilepsy, stroke, and neurodegenerative diseases. Its ability to block AMPA/kainate receptors helps in understanding the mechanisms underlying memory, learning, and neuronal damage. Additionally, it serves as a valuable tool in pharmacological studies to develop therapeutic agents targeting glutamate-related pathways.